Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
Adam Strzelczyk, Susanne Schubert‐Bast
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 217-237
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Adam Strzelczyk, Susanne Schubert‐Bast
CNS Drugs (2022) Vol. 36, Iss. 10, pp. 1079-1111
Open Access | Times Cited: 95
Dravet syndrome: A systematic literature review of the illness burden
Adam Strzelczyk, Lieven Lagae, Jo M. Wilmshurst, et al.
Epilepsia Open (2023) Vol. 8, Iss. 4, pp. 1256-1270
Open Access | Times Cited: 33
Fenfluramine: a plethora of mechanisms?
Jo Sourbron, Lieven Lagae
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 28
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Simona Lattanzi, Eugen Trinka, Emilio Russo, et al.
Drugs (2023) Vol. 83, Iss. 15, pp. 1409-1424
Open Access | Times Cited: 26
Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy
Danfeng Cao, Xinyu Zhou, Qian Guo, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
Renzo Guerrini, Catherine Chiron, Delphine Vandame, et al.
Epilepsia Open (2024) Vol. 9, Iss. 2, pp. 689-703
Open Access | Times Cited: 10
Adaptive functioning and neurodevelopment in patients with Dravet syndrome: 12-month interim analysis of the BUTTERFLY observational study
Joseph Sullivan, Elaine Wirrell, Kelly G. Knupp, et al.
Epilepsy & Behavior (2024) Vol. 151, pp. 109604-109604
Open Access | Times Cited: 9
A Highly Sensitive Triple Quad LC–MS/MS Method Development and Validation for the Determination of Bexicaserin (LP352) in Human Plasma and Urine Matrices
Raja Reddy Kallem, Meredith Yeager, Rebecca L. Chan, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 2
Closed Access | Times Cited: 1
A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies
Elisa Buhleier, Susanne Schubert‐Bast, Susanne Knake, et al.
Epilepsia (2025)
Open Access | Times Cited: 1
Dravet syndrome: Advances in etiology, clinical presentation, and treatment
Zimeng He, Yumei Li, Xiaoyu Zhao, et al.
Epilepsy Research (2022) Vol. 188, pp. 107041-107041
Closed Access | Times Cited: 37
The pharmacological treatment of epilepsy in adults
Torbjörn Tomson, Johan Zelano, Yew Li Dang, et al.
Epileptic Disorders (2023) Vol. 25, Iss. 5, pp. 649-669
Open Access | Times Cited: 22
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
James E. Frampton
Drugs (2023) Vol. 83, Iss. 10, pp. 923-934
Open Access | Times Cited: 19
Emotional experiences of family caregivers of children with Dravet syndrome
Jan Domaradzki, Dariusz Walkowiak
Epilepsy & Behavior (2023) Vol. 142, pp. 109193-109193
Open Access | Times Cited: 16
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies
Graeme J. Sills
Therapeutic Advances in Neurological Disorders (2023) Vol. 16
Open Access | Times Cited: 16
Sleep quality, anxiety, symptoms of depression, and caregiver burden among those caring for patients with Dravet syndrome: a prospective multicenter study in Germany
Margarita Maltseva, Susanne Schubert‐Bast, Johann Philipp Zöllner, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 15
The efficacy and safety of cannabidiol (CBD) in pediatric patients with Dravet Syndrome: a narrative review of clinical trials
Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 6
Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox–Gastaut syndrome in clinical practice
Elaine Wirrell, Lieven Lagae, Ingrid E. Scheffer, et al.
Epilepsia Open (2024) Vol. 9, Iss. 5, pp. 1643-1657
Open Access | Times Cited: 6
Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox–Gastaut syndrome and literature review
Adam Strzelczyk, Hendrik Becker, Lisa Marie Tako, et al.
Neurological Research and Practice (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 5
Efficacy and safety of adjunctive antiseizure medications for dravet syndrome: A systematic review and network meta-analysis
Jian Wu, Liu Zhang, Xi Zhou, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey
Anne T. Berg, Tracy Dixon‐Salazar, Mary Anne Meskis, et al.
Epilepsy Research (2023) Vol. 200, pp. 107280-107280
Open Access | Times Cited: 12
Efficacy and tolerability of add‐on stiripentol in real‐world clinical practice: An observational study in Dravet syndrome and non‐Dravet developmental and epileptic encephalopathies
António Gil‐Nagel, Ángel Aledo‐Serrano, Álvaro Beltrán‐Corbellini, et al.
Epilepsia Open (2023) Vol. 9, Iss. 1, pp. 164-175
Open Access | Times Cited: 11
Anti-seizure Medications: Challenges and Opportunities
Neha Tandon, Milica Radosavljević, Danijela Vučević, et al.
CNS & Neurological Disorders - Drug Targets (2024) Vol. 23, Iss. 9, pp. 1120-1133
Closed Access | Times Cited: 4
Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil
Pengpeng Wu, Birong Cao, Fuyun Tian, et al.
Neuroscience Bulletin (2023) Vol. 40, Iss. 5, pp. 594-608
Closed Access | Times Cited: 11
Off-label-Use von anfallssuppressiver und immunsuppressiver Medikation bei Epilepsien
Adam Strzelczyk, Sebastian von Stuckrad-Barre, Gerhard Kurlemann, et al.
Deleted Journal (2025)
Open Access
Communicating a diagnosis of Dravet syndrome to parents/caregivers: An international Delphi consensus
Andreas Brunklaus, Susanne Schubert‐Bast, Francesca Darra, et al.
Epilepsia Open (2025)
Open Access
Page 1 - Next Page

Scroll to top